IDH2 and acute myeloid leukemia: The clinical trials that led to the approval of IDH inhibitors by the FDA revealed that 11–14% patients with R/R AML develop DS [97,101], which is managed with corticosteroids, hydroxyurea, and temporary discontinuation of IDH inhibitors.